NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
R Trondl, P Heffeter, MA Jakupec, W Berger… - BMC Pharmacology and …, 2012 - Springer
۳۱ ارجاع2012
Background NKP-1339 is one of the most promising investigational non-platinum metal drugs in clinical development against solid malignancies. Recently, NKP-1339 was evaluated in …